메뉴 건너뛰기
Library Notice
Institutional Access
If you certify, you can access the articles for free.
Check out your institutions.
ex)Hankuk University, Nuri Motors
Log in Register Help KOR
Subject

Statin Therapy and the Risk of Osteoporotic Fractures in Patients with Metabolic Syndrome: a Nested Case-Control Study
Recommendations
Search

논문 기본 정보

Type
Academic journal
Author
Kim Kyoung Jin (Division of Endocrinology and Metabolism Department of Internal Medicine Korea University College o) Choi Jimi (Department of Biostatistics Korea University College of Medicine Seoul Korea.) Kim Ji Yoon (Division of Endocrinology and Metabolism Department of Internal Medicine Korea University College o)
Journal
한국지질동맥경화학회(구 한국지질학회) 지질·동맥경화학회지 지질·동맥경화학회지 제10권 제3호 KCI Accredited Journals
Published
2021.9
Pages
322 - 333 (12page)
DOI
10.12997/jla.2021.10.3.322

Usage

cover
Statin Therapy and the Risk of Osteoporotic Fractures in Patients with Metabolic Syndrome: a Nested Case-Control Study
Ask AI
Recommendations
Search

Abstract· Keywords

Report Errors
Objective: We aimed to investigate the association between statin use and the risk of major osteoporotic fractures in patients with metabolic syndrome (MetS). Methods: A nested case-control study was performed in patients with MetS (≥50 years) who had no history of osteoporotic fracture using the Korean National Health Insurance Service- Health Screening Cohort. This study included 17,041 patients diagnosed with new-onset osteoporotic fractures and controls matched in a 1:1 ratio by age, sex, body mass index, cohort entry date, and follow-up duration. Conditional logistic regression analysis was used to evaluate covariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Results: During a 4-year follow-up period, the risk of major osteoporotic fractures was significantly reduced by 9% (OR, 0.91; 95% CI, 0.85?0.97) in statin users compared with that in non-users. Among subtypes of major osteoporotic fracture, a risk reduction with statin therapy was significant for vertebral fracture (OR, 0.86; 95% CI, 0.79?0.94) but not for non-vertebral fracture (OR, 0.97; 95% CI, 0.88?1.06). Longer duration (OR, 0.97; 95% CI, 0.96?0.99, per 1-year increase) and higher cumulative dose (OR, 0.97; 95% CI, 0.95?0.99, per 365 defined daily doses) of statins were negatively associated with the risk of major osteoporotic fracture. Conclusion: This study supports the hypothesis that statin therapy has a beneficial effect on major osteoporotic fractures, especially vertebral fractures, in patients with MetS.

Contents

No content found

References (64)

Add References

Recommendations

It is an article recommended by DBpia according to the article similarity. Check out the related articles!

Related Authors

Recently viewed articles

Comments(0)

0

Write first comments.